News of Patient Death Has No Impact on Selecta’s Lead Program
Insights - Selecta released an 8-K after market today which disclosed that one of the patients in the SEL-403 trial died from a Grade 5 Serious Adverse … Continue Reading
Read NowInsights
Bellus Well Positioned Following Menlo’s Cough Flop
Insights - Menlo (MNLO), a company developing serlopitant for chronic cough candidate, reported disappointing Phase 2 data. In 185 patients, serlopitant group had 31% less reduction than the placebo group. In … Continue Reading
Read NowWhat to Expect from Selecta’s Phase 2 data in October 2018
Insights - Selecta will present their “5+0” co-administered Phase 2 data at the American College Rheumatology (ACR) conference held October 19-24 in Chicago. What to expect 1. … Continue Reading
Read Now
FDA Under Enormous Pressure To Approve Fennec’s STS Drug Under Wide Label Following Testimony At Little-Known Patient Advocacy Event on September 13
Insights - For the first time since PropThink launched in late 2012, we travelled to a Patient Advocacy Meeting in Maryland – to see and hear from … Continue Reading
Premium: Read NowLow Data Hurdle Makes Bellus Attractive Ahead of Q4 Catalyst
Insights - In December, Bellus Health (BLUSF:OTC) (BLU:TSX) will report Phase 1 data for their chronic cough candidate BLU-5937. Bellus’ candidate is a P2X3 inhibitor, a class … Continue Reading
Read NowSelecta’s Highly Anticipated Phase 2 Data Expected in October
Insights - Selecta released Q2 2018 results and announced updates regarding their Phase 2 SEL-212 5+0 dosing and Phase 3 plans. Here are main takeaways: 5+0 dosing to be … Continue Reading
Read NowEarly EMA Discussions Suggesting Wide Label Approval for Fennec
Insights - The pediatric committee at the European Medicines Agency (EMA) held discussions last week on Fennec’s STS, which is nearing a MAA submission sometime in Q4. The title … Continue Reading
Premium: Read Now